Sjögren's disease & overlap diseases
Clinical implication and tissue-specific activation of the OX40-OX40L costimulatory pathway in Sjögren's disease
Authors' conclusion
The OX40-OX40L pathway shows distinct patterns of activation in systemic and glandular immune compartments in SjD.
Study context
- Population
- Patients with Sjögren's disease and healthy controls
- Exposure
- Sjögren's disease (SjD) patients vs healthy controls
- Outcome
- Expression of the OX40-OX40L pathway (serum OX40 and OX40L; minor salivary gland expression) and its association with clinical and immunologic features
Methodological detailscase-control comparison with healthy controls (HCs), ELISA, immunohistochemistry and immunofluorescence of minor salivary gland biopsies
- Case-control comparison with HCs
- ELISA
- Immunohistochemistry and immunofluorescence of minor salivary gland biopsies
Main finding
As reported in the abstract
OX40-OX40L pathway expression
- Serum OX40 significantly elevated in SjD vs HCs
- Serum OX40 positively correlated with systemic disease activity and serum β2-microglobulin
- Higher serum OX40 in SjD patients with leukopenia and lymphadenopathy
- In minor salivary gland tissue, OX40 and OX40L expression increased with higher focus scores
- OX40 localised to CD4+ and CD8+ T cells; OX40L to glandular epithelial cells and infiltrating B cells
Observational data: associations, not effects.
Original publication
Clinical implication and tissue-specific activation of the OX40-OX40L costimulatory pathway in Sjögren's disease. Clin Exp Rheumatol. Published 24 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →